Amendment to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Previously presented) A chemical compound having the formula (I)

(I)



wherein,

R_1 is selected from the group consisting of hydrogen, allyl of 1 to 6 carbon atoms, unsubstituted phenyl, and substituted phenyl;

R_2 is selected from the group consisting of H, alkene, un-substituted phenyl, and substituted phenyl; or a pharmaceutically acceptable salt thereof.

Claim 2. (Original) The chemical compound according to claim 1, wherein at least one of R_1 and R_2 is hydrogen.

Claim 3. (Original) The chemical compound according to claim 1, wherein R_1 is hydrogen.

Claim 4. (Original) The chemical compound according to claim 1, wherein R_2 is hydrogen.

Claim 5. (Previously presented) The chemical compound of claim 1, wherein R_1 is hydrogen; and R_2 is hydrogen; and pharmaceutically acceptable salts thereof.

Claim 6. (Previously presented) A method of preparing the chemical compound according to claim 5, comprising:

contacting 3,4-methylenedioxybenzoylhydrazine with an equimolar amount of thiophene-2-carboxaldehyde; and recovering the compound.

Claim 7. (Previously presented) The method according to claim 6, wherein said thiophene-2-carboxaldehyde is in a solvent and in the presence of a catalyst.

Claim 8. (Original) The method according to claim 7, wherein said solvent is ethanol and said catalyst is hydrochloric acid.

Claim 9. (Previously presented) A method of treating congestive heart failure in a patient, comprising administering a therapeutically effective amount of the compound of claim 5.

Claim 10. (Original) The method of treating a patient according to claim 9, wherein the therapeutically effective amount of the compound is one that produces a plasma concentration of the compound of 1 μM to 100 μM.

Claim 11. (Original) The method of treating a patient according to claim 10, wherein the therapeutically effective amount is one that produces a plasma concentration of the compound of 10 μM to 50 μM.

Claims 12-15. (Canceled)

Claim 16. (Previously presented) A pharmaceutical composition comprising the compound of claim 5 in combination with a pharmaceutically acceptable carrier.

Claim 17. (Previously presented) The pharmaceutical composition of claim 16, further comprising pharmaceutically acceptable inactive ingredient selected from diluents, solvents, disintregrants, lubricants, stabilizers, or coatings.

Claim 18. (Original) The pharmaceutical composition of claim 17, wherein the composition is formulated for oral administration.

Claim 19. (Previously presented) The pharmaceutical composition of claim 16, wherein the composition is formulated for parentral administration.

Claims 20 and 21. (Canceled)

Claim 22. (Previously presented) A pharmaceutical composition, comprising the compound of Claim 1 in combination with a pharmaceutically acceptable carrier.

Claim 23. (Previously presented) A pharmaceutical composition, comprising the compound of claim 2 in combination with a pharmaceutically acceptable carrier.

Claim 24. (Previously presented) A pharmaceutical composition, comprising the compound of Claim 3 in combination with a pharmaceutically acceptable carrier.

Claim 25. (Previously presented) A pharmaceutical composition, comprising the compound of Claim 4 in combination with a pharmaceutically acceptable carrier.

Claim 26. (Previously presented) A method of treating congestive heart failure in a patient, comprising administering a therapeutically effective amount of the compound of claim 3.

Claim 27. (Previously presented) A method of treating congestive heart failure in a patient, comprising administering a therapeutically effective amount of the compound of claim 4.